On June 6, 2024, Exicure, Inc., a biotechnology company based in Chicago, Illinois, filed a Form 8-K with the SEC, reporting its financial and operational results for the fiscal year ended December 31, 2023. The company disclosed a significant decrease in cash and cash equivalents from $8.6 million at the end of 2022 to $0.8 million at the end of 2023, with a further reduction to approximately $0.2 million by May 31, 2024. To address its funding needs, Exicure received a $700,000 loan from DGP Co., Ltd., a major stockholder, on June 3, 2024. The loan carries a 6.0% annual interest rate and matures ten months from issuance. Research and development expenses dropped from $19.8 million in 2022 to $1.4 million in 2023 following the company's suspension of all research and development activities. General and administrative expenses increased by $1.8 million due to the reclassification of certain costs. Exicure reported a net loss of $16.9 million for 2023, a significant increase from the $2.6 million net loss in 2022. The company has indicated that it requires substantial additional financing to continue operations and is exploring strategic alternatives to maximize stockholder value.

On June 6, 2024, Exicure, Inc., a biotechnology company based in Chicago, Illinois, filed a Form 8-K with the SEC, reporting its financial and operational results for the fiscal year ended December 31, 2023. The company disclosed a significant decrease in cash and cash equivalents from $8.6 million at the end of 2022 to $0.8 million at the end of 2023, with a further reduction to approximately $0.2 million by May 31, 2024. To address its funding needs, Exicure received a $700,000 loan from DGP Co., Ltd., a major stockholder, on June 3, 2024. The loan carries a 6.0% annual interest rate and matures ten months from issuance. Research and development expenses dropped from $19.8 million in 2022 to $1.4 million in 2023 following the company's suspension of all research and development activities. General and administrative expenses increased by $1.8 million due to the reclassification of certain costs. Exicure reported a net loss of $16.9 million for 2023, a significant increase from the $2.6 million net loss in 2022. The company has indicated that it requires substantial additional financing to continue operations and is exploring strategic alternatives to maximize stockholder value.